ArticleJournal of medical biochemistry2026
Prognostic value of the HALP index, erythrocyte sedimentation rate, and rheumatoid factor in rheumatoid arthritis: A laboratory-based multivariate analysis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biochemical and hematological indices play a critical role in evaluating systemic inflammation and disease activity in rheumatoid arthritis (RA). This study investigated the prognostic value of the hemoglobin-albumin-lymphocyte-platelet (HALP) index, in combination with erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF), for predicting RA disease progression. Methods: A retrospective analysis was performed on 146 RA patients admitted between December 2022 and December 2023. Laboratory variables included HALP index, ESR, RF, C-reactive protein, anti-CCP antibodies, hemoglobin, albumin, lymphocyte and platelet counts, and serum creatinine. Measurements were obtained using standardized automated hematology and biochemical analyzers. Disease activity and radiographic joint damage scores were also assessed. Statistical approaches included correlation analysis, regression analysis, and receiver operating characteristic (ROC) curve evaluation. Results: The HALP index, ESR, and RF were significantly associated with RA disease progression. The HALP index demonstrated a strong correlation with disease activity (r=0.602, P<0.001). ROC analysis showed an area under the curve (AUC) of 0.858 for HALP, 0.841 for ESR, and 0.924 for RF. When combined in a multivariate regression model, the predictive performance improved (AUC=0.943). Conclusions: The HALP index, as a composite biochemical marker, in combination with ESR and RF provides significant prognostic information for RA progression. These findings underscore the importance of laboratory-based indices in refining prognostic assessments and highlight their potential role in personalized disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.